Publicou 6 edições por ano
ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472
Indexed in
Botulinum Neurotoxin Vaccines: Past, Present, and Future
RESUMO
In the early 1930s, a formalin-inactivated toxoid against botulinum neurotoxin was first tested in humans. In 1965, a pentavalent botulinum toxoid (PBT) received Investigational New Drug (IND) status under the Centers for Disease Control's IND 161 (for at-risk workers), and in 1991 under the United States Army's Office of the Surgeon General IND 3723 (for military deployment). This PBT vaccine has been shown to be safe, with over 20,000 injections given to date, and continues to be used in at-risk individuals. During the past decade, recombinant DNA technology has been employed to develop second-generation vaccines to prevent botulism. Recombinant subunit vaccines utilizing the receptor-binding domains of botulinum neurotoxin (BoNT) have been shown to be safe and efficacious in protecting animal models against BoNT serotypes A, B, C1, D, E, and F. In 2004, the first recombinant subunit vaccine [rBV A/B (Pichia pastoris) vaccine] was tested in humans during a phase I clinical trial. Results from that study demonstrated that the recombinant bivalent vaccine was safe and well tolerated at all dosage levels tested and stimulated serotype-specific neutralizing antibodies among the majority of vaccine recipients.
-
Smith Leonard A., Rusnak Janice M., Botulism Vaccines and the Immune Response, in Botulinum Toxin, 2009. Crossref
-
Naumann Markus, Boo Lee Ming, Ackerman Alan H., Gallagher Conor J., Immunogenicity of botulinum toxins, Journal of Neural Transmission, 120, 2, 2013. Crossref
-
Zdanovsky Alexey, Zdanovsky Denis, Zdanovskaia Maria, Epitope mapping of botulinum neurotoxins light chains, Toxicon, 60, 7, 2012. Crossref
-
Pittman Phillip R., Plotkin Stanley A., Biodefense and special pathogen vaccines, in Vaccines, 2013. Crossref
-
Ma Yao, An Huai-Jie, Wei Xiao-Qi, Xu Qing, Yu Yun-Zhou, Sun Zhi-Wei, Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant, Human Vaccines & Immunotherapeutics, 9, 2, 2013. Crossref
-
Yu Yun-Zhou, Guo Jin-Peng, An Huai-Jie, Zhang Shu-Ming, Wang Shuang, Yu Wei-Yuan, Sun Zhi-Wei, Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors, Vaccine, 31, 20, 2013. Crossref
-
Hu Xin, Legler Patricia M., Southall Noel, Maloney David J., Simeonov Anton, Jadhav Ajit, Structural insight into exosite binding and discovery of novel exosite inhibitors of botulinum neurotoxin serotype A through in silico screening, Journal of Computer-Aided Molecular Design, 28, 7, 2014. Crossref
-
Shi Xuerong, Garcia Gregory E., Neill Roger J., Gordon Richard K., TCEP treatment reduces proteolytic activity of BoNT/B in human neuronal SHSY-5Y cells, Journal of Cellular Biochemistry, 107, 5, 2009. Crossref
-
Stahl Andrea M., Adler Michael, Millard Charles B., Gilfillan Lynne, Accelerating botulism therapeutic product development in the Department of Defense, Drug Development Research, 70, 4, 2009. Crossref
-
Ramasamy S, Liu CQ, Tran H, Gubala A, Gauci P, McAllister J, Vo T, Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents, British Journal of Pharmacology, 161, 4, 2010. Crossref
-
Böhnel H., Gessler F., Neurotoxigenic Clostridia, in Pathogenesis of Bacterial Infections in Animals, 2010. Crossref
-
Basiri Mohsen, Mousavi Seyed Latif, Basiri Hossein, Rasooli Iraj, An epitopic approach to designing and characterization of a multiple antigenic polypeptide against Botulinum neurotoxins A and E, World Journal of Microbiology and Biotechnology, 26, 9, 2010. Crossref
-
Hudacek Andrew W, Al-Saleem Fetweh H, Willet Mallory, Eisemann Travis, Mattis Jeffrey A, Simpson Lance L, Schnell Matthias J, Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo, Molecular Therapy - Methods & Clinical Development, 1, 2014. Crossref
-
Yu YunZhou, Liu Si, Ma Yao, Gong Zheng-Wei, Wang Shuang, Sun Zhi-Wei, Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors, Human Vaccines & Immunotherapeutics, 10, 7, 2014. Crossref
-
Yu YunZhou, Shi DanYang, Liu Si, Gong Zheng-Wei, Wang Shuang, Sun ZhiWei, Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system, Human Vaccines & Immunotherapeutics, 11, 2, 2015. Crossref
-
Rosen Osnat, Feldberg Liron, Gura Sigalit, Zichel Ran, A new peptide substrate for enhanced botulinum neurotoxin type B detection by endopeptidase–liquid chromatography–tandem mass spectrometry/multiple reaction monitoring assay, Analytical Biochemistry, 473, 2015. Crossref
-
Henkel James S., Tepp William H., Przedpelski Amanda, Fritz Robert B., Johnson Eric A., Barbieri Joseph T., Subunit vaccine efficacy against Botulinum neurotoxin subtypes, Vaccine, 29, 44, 2011. Crossref
-
Stahl Christina, Unger Lucia, Mazuet Christelle, Popoff Michel, Straub Reto, Frey Joachim, Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D, Vaccine, 27, 41, 2009. Crossref
-
Yu Yunzhou, Yu Jiyu, Li Na, Wang Shuang, Yu Weiyuan, Sun Zhiwei, Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors, Vaccine, 27, 44, 2009. Crossref
-
Yu Yun-Zhou, Wang Wen-Bin, Li Na, Wang Shuang, Yu Wei-Yuan, Sun Zhi-Wei, Enhanced potency of individual and bivalent DNA replicon vaccines or conventional DNA vaccines by formulation with aluminum phosphate, Biologicals, 38, 6, 2010. Crossref
-
Yu Yun-Zhou, Li Na, Zhu Heng-Qi, Wang Rui-Lin, Du Yun, Wang Shuang, Yu Wei-Yuan, Sun Zhi-Wei, The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate, Vaccine, 27, 21, 2009. Crossref
-
Shearer Jeffry D., Vassar Michelle L., Swiderski William, Metcalfe Karen, Niemuth Nancy, Henderson Ian, Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B), Vaccine, 28, 45, 2010. Crossref
-
Masuyer Geoffrey, Thiyagarajan Nethaji, James Peter L., Marks Philip M.H., Chaddock John A., Acharya K. Ravi, Crystal structure of a catalytically active, non-toxic endopeptidase derivative of Clostridium botulinum toxin A, Biochemical and Biophysical Research Communications, 381, 1, 2009. Crossref
-
Yu Yun-Zhou, Zhang Shu-Ming, Ma Yao, Zhu Heng-Qi, Wang Wen-Bing, Du Yun, Zhou Xiao-Wei, Wang Rui-Lin, Wang Shuang, Yu Wei-Yuan, Huang Pei-Tang, Sun Zhi-Wei, Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F, Clinical Immunology, 137, 2, 2010. Crossref
-
Liu Bo, Shi DanYang, Chang ShaoHong, Gong Xin, Yu YunZhou, Sun ZhiWei, Wu Jun, Characterization and immunological activity of different forms of recombinant secreted Hc of botulinum neurotoxin serotype B products expressed in yeast, Scientific Reports, 5, 1, 2015. Crossref
-
Shearer Jeffry D., Manetz T. Scott, House Robert V., Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B), Vaccine, 30, 11, 2012. Crossref
-
Ben David Alon, Torgeman Amram, Barnea Ada, Zichel Ran, Expression, purification and characterization of the receptor-binding domain of botulinum neurotoxin serotype B as a vaccine candidate, Protein Expression and Purification, 110, 2015. Crossref
-
Lu Shan, Wang Shixia, Technical transformation of biodefense vaccines, Vaccine, 27, 2009. Crossref
-
Smith Leonard A., Botulism and vaccines for its prevention, Vaccine, 27, 2009. Crossref
-
Montgomery Vicki A., Ahmed S. Ashraf, Olson Mark A., Mizanur Rahman M., Stafford Robert G., Roxas-Duncan Virginia I., Smith Leonard A., Ex vivo inhibition of Clostridium botulinum neurotoxin types B, C, E, and F by small molecular weight inhibitors, Toxicon, 98, 2015. Crossref
-
Xie Xinmei, Wang Lin, Yang Wenliang, Yu Ruishuang, Li Qingli, Pang Xiaobin, Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency, Investigational New Drugs, 33, 4, 2015. Crossref
-
Horowitz B Zane, Type E botulism, Clinical Toxicology, 48, 9, 2010. Crossref
-
Zhang Jiu-Cong, Sun Li, Nie Qing-He, Botulism, where are we now?, Clinical Toxicology, 48, 9, 2010. Crossref
-
Guo Jiubiao, Wang Jinglin, Gao Shan, Ji Bin, Waichi Chan Edward, Chen Sheng, Substrate-based inhibitors exhibiting excellent protective and therapeutic effects against Botulinum Neurotoxin A intoxication, Scientific Reports, 5, 1, 2015. Crossref
-
Takahashi Tsuyoshi, Joshi Suresh G., Al-Saleem Fetweh, Ancharski Denise, Singh Ajay, Nasser Zidoon, Simpson Lance L., Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin, Vaccine, 27, 19, 2009. Crossref
-
Yu Yun-Zhou, Zhang Shu-Ming, Wang Wen-Bing, Du Yun, Zhu Heng-Qi, Wang Rui-Lin, Zhou Xiao-Wei, Lin Jian-Bo, Wang Shuang, Yu Wei-Yuan, Huang Pei-Tang, Sun Zhi-Wei, Development and preclinical evaluation of a new F(ab′)2 antitoxin against botulinum neurotoxin serotype A, Biochimie, 92, 10, 2010. Crossref
-
Webb Robert P., Smith Theresa J., Wright Patrick, Brown Jennifer, Smith Leonard A., Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3, Vaccine, 27, 33, 2009. Crossref
-
Harrell William A., Vieira Rebecca C., Ensel Susan M., Montgomery Vicki, Guernieri Rebecca, Eccard Vanessa S., Campbell Yvette, Roxas-Duncan Virginia, Cardellina John H., Webb Robert P., Smith Leonard A., A matrix-focused structure-activity and binding site flexibility study of quinolinol inhibitors of botulinum neurotoxin serotype A, Bioorganic & Medicinal Chemistry Letters, 27, 3, 2017. Crossref
-
Li Na, Yu Yun-Zhou, Yu Wei-Yuan, Sun Zhi-Wei, Enhancement of the immunogenicity of DNA replicon vaccine ofClostridium botulinumneurotoxin serotype A byGM-CSFgene adjuvant, Immunopharmacology and Immunotoxicology, 33, 1, 2011. Crossref
-
Diamant Eran, Lachmi Bat-El, Keren Adi, Barnea Ada, Marcus Hadar, Cohen Shoshana, David Alon Ben, Zichel Ran, Goldman Ellen R., Evaluating the Synergistic Neutralizing Effect of Anti-Botulinum Oligoclonal Antibody Preparations, PLoS ONE, 9, 1, 2014. Crossref
-
Yu Chi Ho, Song Dong Hyun, Choi Jun Young, Joe Hae Eun, Jeong Woo Hyeon, Hur Gyeung Haeng, Shin Young Kee, Jeong Seong Tae, A mutated recombinant subunit vaccine protects mice and guinea pigs against botulinum type A intoxication, Human Vaccines & Immunotherapeutics, 14, 2, 2018. Crossref
-
Horowitz B. Zane, Botulism, in Critical Care Toxicology, 2017. Crossref
-
Pittman Phillip R., Plotkin Stanley A., Biodefense and Special Pathogen Vaccines, in Plotkin's Vaccines, 2018. Crossref
-
Horowitz B. Zane, Botulism, in Critical Care Toxicology, 2017. Crossref
-
Clostridial Diseases, in Diseases of Poultry, 2013. Crossref
-
Staats Herman F., Fielhauer Jeffrey R., Thompson Afton L., Tripp Alice A., Sobel Ashley E., Maddaloni Massimo, Abraham Soman N., Pascual David W., Deepe George, Mucosal Targeting of a BoNT/A Subunit Vaccine Adjuvanted with a Mast Cell Activator Enhances Induction of BoNT/A Neutralizing Antibodies in Rabbits, PLoS ONE, 6, 1, 2011. Crossref
-
Ben David Alon, Diamant Eran, Barnea Ada, Rosen Osnat, Torgeman Amram, Zichel Ran, The Receptor Binding Domain of Botulinum Neurotoxin Serotype A (BoNT/A) Inhibits BoNT/A and BoNT/E Intoxications In Vivo , Clinical and Vaccine Immunology, 20, 8, 2013. Crossref
-
Chellapandi P., Prisilla A., Clostridium botulinum type A-virulome-gut interactions: A systems biology insight, Human Microbiome Journal, 7-8, 2018. Crossref
-
Khouri Jessica M., Motter Ruth N., Arnon Stephen S., Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity, Vaccine, 36, 15, 2018. Crossref
-
Shi Dan-Yang, Chen Bo-Yang, Mao Yun-Yun, Zhou Guo, Lu Jian-Sheng, Yu Yun-Zhou, Zhou Xiao-Wei, Sun Zhi-Wei, Development and evaluation of candidate subunit vaccine against botulinum neurotoxin serotype B, Human Vaccines & Immunotherapeutics, 15, 3, 2019. Crossref
-
Emanuel Andrew, Qiu Hongyu, Barker Douglas, Takla Teresa, Gillum Karen, Neimuth Nancy, Kodihalli Shantha, Gillet Daniel, Efficacy of equine botulism antitoxin in botulism poisoning in a guinea pig model, PLOS ONE, 14, 1, 2019. Crossref
-
Shi Dan-Yang, Liu Fu-Jia, Mao Yun-Yun, Cui Rong-Tian, Lu Jian-Sheng, Yu Yun-Zhou, Dong Xiao-Jie, Yang Zhi-Xin, Sun Zhi-Wei, Pang Xiao-Bin, Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E, Human Vaccines & Immunotherapeutics, 16, 1, 2020. Crossref
-
Boulianne Martine, Uzal Francisco A., Opengart Kenneth, Clostridial Diseases, in Diseases of Poultry, 2020. Crossref
-
Horowitz B. Zane, Botulism, in Critical Care Toxicology, 2015. Crossref
-
Adler Michael, Gul Nizamettin, Eitzen Edward, Oyler George, Molles Brian, Prevention and Treatment of Botulism, in Molecular Aspects of Botulinum Neurotoxin, 2014. Crossref
-
Zichel R., Mimran A., Keren A., Barnea A., Steinberger-Levy I., Marcus D., Turgeman A., Reuveny S., Efficacy of a Potential Trivalent Vaccine Based on Hc Fragments of Botulinum Toxins A, B, and E Produced in a Cell-Free Expression System, Clinical and Vaccine Immunology, 17, 5, 2010. Crossref
-
Held Daniel M., Shurtleff Amy C., Fields Scott, Green Christopher, Fong Julie, Jones Russell G. A., Sesardic Dorothea, Buelow Roland, Burke Rae Lyn, Vaccination of Rabbits with an Alkylated Toxoid Rapidly Elicits Potent Neutralizing Antibodies against Botulinum Neurotoxin Serotype B, Clinical and Vaccine Immunology, 17, 6, 2010. Crossref
-
Sanford Daniel C., Barnewall Roy E., Vassar Michelle L., Niemuth Nancy, Metcalfe Karen, House Robert V., Henderson Ian, Shearer Jeffry D., Inhalational Botulism in Rhesus Macaques Exposed to Botulinum Neurotoxin Complex Serotypes A1 and B1, Clinical and Vaccine Immunology, 17, 9, 2010. Crossref
-
Clapp Beata, Golden Sarah, Maddaloni Massimo, Staats Herman F, Pascual David W, Adenovirus F protein as a delivery vehicle for botulinum B, BMC Immunology, 11, 1, 2010. Crossref
-
Sonkar Priyanka, Chauhan Vinita, Chauhan Ritika, Saxena Nandita, Dhaked Ram Kumar, Characterization of immune response induced against catalytic domain of botulinum neurotoxin type E, Scientific Reports, 10, 1, 2020. Crossref
-
Xu Q, Pichichero M E, Simpson L L, Elias Md, Smith L A, Zeng M, An adenoviral vector-based mucosal vaccine is effective in protection against botulism, Gene Therapy, 16, 3, 2009. Crossref
-
Przedpelski Amanda, Tepp William H., Kroken Abby R., Fu Zhuji, Kim Jung-Ja P., Johnson Eric A., Barbieri Joseph T., Bäumler A. J., Enhancing the Protective Immune Response against Botulism, Infection and Immunity, 81, 7, 2013. Crossref
-
Mechaly Adva, Diamant Eran, Alcalay Ron, Ben David Alon, Dor Eyal, Torgeman Amram, Barnea Ada, Girshengorn Meni, Levin Lilach, Epstein Eyal, Tennenhouse Ariel, Fleishman Sarel J., Zichel Ran, Mazor Ohad, Highly Specific Monoclonal Antibody Targeting the Botulinum Neurotoxin Type E Exposed SNAP-25 Neoepitope, Antibodies, 11, 1, 2022. Crossref
-
Ben David Alon, Papir Yoel, Hazan Ophir, Redelman Moses, Diamant Eran, Barnea Ada, Torgeman Amram, Zichel Ran, High Cell Density Cultivation Process for the Expression of Botulinum Neurotoxin a Receptor Binding Domain, Toxins, 14, 4, 2022. Crossref
-
Sepulveda Jorge, Mukherjee Jean, Tzipori Saul, Simpson Lance L., Shoemaker Charles B., Efficient Serum Clearance of Botulinum Neurotoxin Achieved Using a Pool of Small Antitoxin Binding Agents, Infection and Immunity, 78, 2, 2010. Crossref
-
Ben David Alon, Barnea Ada, Torgeman Amram, Diamant Eran, Dor Eyal, Schwartz Arieh, Rosen Osnat, Caspi Noa, Saraf Miki, Lerer Elad, Adar Yaakov, Lupo Edith, Toister Einat, Zichel Ran, Immunologic and Protective Properties of Subunit- vs. Whole Toxoid-Derived Anti-Botulinum Equine Antitoxin, Vaccines, 10, 9, 2022. Crossref